OraSure Technologies (NASDAQ:OSUR) Lowered to “Hold” Rating by StockNews.com

StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research note released on Saturday.

OraSure Technologies Stock Performance

Shares of OraSure Technologies stock opened at $3.80 on Friday. The stock has a market capitalization of $283.44 million, a price-to-earnings ratio of 25.33 and a beta of 0.05. OraSure Technologies has a 52-week low of $3.52 and a 52-week high of $8.04. The company’s 50 day moving average price is $3.80 and its 200-day moving average price is $4.03.

Institutional Trading of OraSure Technologies

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in shares of OraSure Technologies by 27.2% in the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock worth $3,655,000 after purchasing an additional 183,191 shares during the last quarter. Franklin Resources Inc. grew its position in shares of OraSure Technologies by 28.5% in the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock worth $1,091,000 after buying an additional 59,723 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of OraSure Technologies by 5.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock worth $3,621,000 after buying an additional 46,216 shares during the last quarter. Barclays PLC boosted its holdings in OraSure Technologies by 182.6% in the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock valued at $836,000 after acquiring an additional 126,503 shares in the last quarter. Finally, Exchange Traded Concepts LLC bought a new stake in OraSure Technologies in the fourth quarter valued at $287,000. 93.50% of the stock is owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.